500 million oral hypoglycemic drugs in East China all specifications have been reviewed!

Recently, Huadong Medicine welcomes good news in the field of oral hypoglycemic drugs.

Figure 1: Information of Huadong Medicine's over-evaluated products

Source: NMPA official website

Pioglitazone hydrochloride tablets are thiazolidinedione insulin sensitizers, which mainly reduce blood sugar by increasing the sensitivity of target cells to insulin

Figure 2: Sales of pioglitazone hydrochloride tablets

Source: Mi Nei.

According to data from Meinenet, in the last three years, the sales of pioglitazone hydrochloride tablets in China’s urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have remained above 500 million yuan in 2020.

Figure 3: East China's next blockbuster oral hypoglycemic drug approved

Source: Meinenet MED2.

In June of this year, East China's Metformin Enpagliflozin Tablets (I) was approved for the first imitation, adding a major player to the company's oral hypoglycemic product line

Source: CDE official website, Minet database

The review data statistics are as of August 20, if there are any errors or omissions, please correct me